5.425USD+3.83%Mkt Cap: 17.64M USDP/E: —Last update: 2026-05-26
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD c…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap17.64M USD
Enterprise Value-11.03M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-45.52M USD
Revenue/Share—
Last Price5.425 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees24
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.67
PEG—
EV/EBITDA0.30
EV/Revenue—
P/S—
P/B0.88
EPS (TTM)-11.84
EPS (Forward)-7.68
52W Range
3.9359% of range20.00
52W High20.00 USD
52W Low3.935 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-242.72%
ROA-73.09%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-31.51M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-74.53%
Net Debt-27.58M USD
Net Debt/EBITDA0.75
Balance Sheet
Debt/Equity1.28
Current Ratio1.73
Quick Ratio1.66
Book Value/Sh5.893 USD
Cash/Share10.39 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:20
Split DateJul 14, 2025
Analyst Consensus
Rating—
Target (Mean)11.40 USD
Target Range7.000 USD – 23.00 USD
# Analysts5
Ownership
Shares Out.3.21M
Float2.89M
Insiders0.41%
Institutions58.33%
Short Interest
Short Ratio1.2d
Short % Float5.64%
Short % Out.4.52%
Shares Short145.03K
Short (prev mo.)114.50K
Technical
SMA 506.905 (-21.4%)
SMA 2008.525 (-36.4%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)116.37K
Avg Vol (10d)62.93K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—